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Objectives: The aim of this study was to determine the extent of autonomic 
dysfunction in patients with clinically isolated syndrome (CIS) by using a 
standardized battery of autonomic tests in the form of the composite autonomic 
scoring scale (CASS). 
Methods: This was a prospective, cross sectional study which included 24 
consecutive patients who were diagnosed with CIS and 17 healthy controls. In all 
participants, heart rate and blood pressure responses to the Valsalva maneuver, 
heart rate response to deep breathing and blood pressure response to passive 
tilt were performed. In 16 patients, Quantitative Sudomotor Axon Reflex Test 
(QSART) and catecholamine measurement was performed. 
Results:  The proportion of CIS patients with pathological adrenergic index was 
statistically significantly higher compared to healthy controls (12 vs 2, p=0.018), 
while there was no difference in cardiovagal index between groups. Five patients 
had a sudomotor index of 1 (in 4 there was hypohydrosis < 50% and in 1 
persistent foot hyperhydrosis). When combining adrenergic, cardiovagal and 
sudomotor index into CASS, 8 patients (50%) had evidence of autonomic 
dysfunction, 7 mild and one moderate.  
Conclusion: Sympathetic nervous system is frequently affected in CIS patients. 
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 Composite autonomic scoring scale detected sympathetic nervous system 
dysfunction in half of the clinically isolated syndrome (CIS) patients. 
 The parasympathetic nervous system seems to be preserved in the early 
stages of multiple sclerosis. 
 Quantitative Sudomotor Axon Reflex Test detects sudomotor dysfunction 





Autonomic nervous system (ANS) is frequently affected in patients with multiple 
sclerosis (MS), and affection of cardiovascular, thermoregulatory, genito-urinary 
and gastrointestinal parts of the ANS has been described with varying 
percentages in MS patients (Adamec and Habek, 2013).  
Alterations to the cardiovascular system are particularly worrisome because 
they may result in orthostatic intolerance and cardiac arrhythmia (Jurić et al., 
2012). Moreover, in MS patients who fall, dysregulation of the ANS could be 
another explanation beside cerebellar or pyramidal involvement. (Merkelbach et 
al. 2006) It is interesting however, that asymptomatic changes in the orthostatic 
reaction seem to outweigh symptomatic abnormalities. (Merkelbach et al. 2006)  
As the cardiovascular reflex mechanisms tested in autonomic laboratories are 
mainly controlled by baroreflexes, which are controlled by the nuclei in the 
brainstem, it is thought that involvement of the brainstem by a demyelinating 
process is responsible for ANS dysfunction in MS. There are limited numbers of 
studies investigating the correlation between MRI disease burden and ANS 
dysfunction. It has been shown that midbrain MS lesions account for most of the 
cardiovascular abnormalities in MS patients, but hemispheric MS lesions also 
seemed to be involved. (Saari et al., 2004) Others have shown that ANS 
dysfunction in MS was correlated with spinal cord cross-sectional area reduction 
but not with spinal cord hyperintensities, indicating that ANS dysfunction is 
more closely related to axonal loss, rather than demyelinating lesions. (de Seze et 
al., 2001) Furthermore, several studies have shown that ANS dysfunction 
correlates with the disease duration and disability measured with expanded 
disability status scale (EDSS), further suggesting that axonal loss may be 
responsible for ANS dysfunction in MS. (Gunal et al., 2002; Kale et al., 2009; de 
Seze et al., 2001) 
Another aspect of cardiovascular dysfunction in MS is exercise capacity. Exercise 
and physical rehabilitation in MS is very important because they lead to 
enhancement of physical fitness and muscle strength, and improvement in 
quality of life. Several studies have investigated heart rate and blood pressure 
responses to incremental dynamic exercise protocols in people with MS. These 
studies revealed that some MS patients failed to increase heart rate and/or 
systolic blood pressure sufficiently, as compared with the control group. (Hansen 
et al. 2013; Hale et al., 2009)  
Different prevalence of cardiovascular autonomic dysfunction can be explained 
with different tests used to investigate both, sympathetic (adrenergic and 
cholinergic) and parasympathetic functions, and different populations of 
patients enrolled in these studies. The correlation between single autonomic 
tests is weak suggesting that different tests measure different aspects and/or 
different anatomical areas within the ANS. (Merkelbach et al. 2006) The most 
commonly used tests for parasympathetic nervous system are Valsalva ratio, 
heart rate response to deep breathing, the 30/15 ratio and for sympathetic 
nervous system blood pressure response to Valsava ratio (however with 
different interpretation of the Valsalva curve), isometric hand grip, blood 
pressure response to passive tilt-up test. (Gunal et al., 2002; Hale et al., 2009; 
McDougall and McLeod., 2003; Acevedo et al., 2000; Kodounis et al., 2005) 
Nevertheless, the common denominator from these studies is that the 
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sympathetic nervous system is affected in the acute stages of MS (relapses), 
while the affectibility of parasympathetic nervous system progresses with the 
disease duration and EDSS. (Nasseri et al., 1999; Flachenecker et al., 2001)  
Testing the thermoregulatory autonomic function is another problem, because 
most of the tests used cannot quantitatively identify differences in sweating or 
determine whether diminished sweating is due to a decreased number of active 
sweat glands, altered innervation of the glands, and/or reduced output from 
activated glands. (Low, 1993) One of the most commonly employed tests for the 
testing of sudomotor function is a sympathetic skin response (SSR). One study 
indicated that that SSR is a useful tool for assessment of autonomic function and 
can be complementary to EDSS and other electrophysiological studies in patients 
with MS and CIS. (Aghamollaii et al., 2011) Despite this, SSR is not commonly 
used in clinical practice because current procedures are not sufficiently reliable 
for diagnostic purposes and it shows imperfect correlations both with clinical 
features and other measurements of autonomic, in particular, sudomotor 
dysfunction. (Vetrugno et al., 2003) On the other hand, good evidence exists that 
Quantitative Sudomotor Axon Reflex Test (QSART) detects a diminished 
peripheral sweating response as a consequence of impairments in autonomic 
control of sudomotor function in MS patients (Davis et al., 2010). 
To overcome these shortcomings in ANS research a standardized battery of 
autonomic tests, preferably in the form of a grading scale, which enables 
diagnosis, grading, and follow-up of autonomic dysfunction, is needed. One such 
scale is the Composite Autonomic Scoring Scale (CASS), which covers all these 
prerequisites in disorders of peripheral and central nervous system with ANS 
involvement (Davis et al., 2005).  
Taking all of this into account, and the fact that the ANS has never been 
systematically investigated in patients with an initial demyelinating event 
suggestive of MS (clinically isolated syndrome - CIS), the aim of this study was to 
determine the extent of autonomic dysfunction in patients with CIS by using a 







This was a prospective, cross sectional study which included consecutive 
patients who were diagnosed with a first clinical symptom of multiple sclerosis 
(CIS) from the 1st of August 2014 until 1st of February 2015 at the Department of 
Neurology, University Hospital Center Zagreb - a tertiary medical center and a 
referral center for multiple sclerosis. Diagnosis of CIS was made with the 
following criteria: 1) acute or subacute development of neurological symptoms 
and/or signs lasting longer than 48 hours in the absence of fever or infection, 2) 
brain and spinal cord MRI showing at least 2 demyelinating lesions larger than 3 
mm or 1 lesion larger than 3 mm that corresponded to the symptom and/or sign, 
3) CSF analysis was performed in all patients for cells, protein level and presence 
of oligoclonal IgG bands (OCB). Age and gender matched controls participated in 
the cardiovascular autonomic system testing.  
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A subset of CIS patients participated in the Quantitative Sudomotor Axon Reflex 
Test (QSART) and catecholamine measurement portion of the study.  
Ethical committees of the University Hospital Center Zagreb and University of 
Zagreb, School of Medicine approved the study. All participants signed informed 
consent. 
 
2.2.Cardiovascular autonomic system testing 
 
All tests were performed in a quiet and dimly lit room. Patients were instructed 
not to drink coffee, smoking or intake of nicotine containing substitutes the 
morning before the testing. Blood pressure and heart rate values were recorded 
using Task Force Monitor (TFM) (CNSystems Medizintechnik AG, Austria). After 
the patient was supine on the testing table, pressure cuff and ECG electrodes 
were adjusted at appropriate sites. A peripheral vein catheter was installed in 
the antecubital or radial vein of the right arm, and 15 minutes of settling period 
was given before recording.  
The following tests were performed as described previously (Freeman, 2006; 
Novak, 2011): heart rate and blood pressure responses to Valsalva maneuver, as 
a measure of parasympathetic and sympathetic function, respectively; heart rate 
response to deep breathing as a measure of parsymapthetic function and blood 
pressure response to passive tilt in the duration of 10 minutes, as a measure of 
sympathetic function.  
The Valsalva maneuver was performed in the supine position by blowing for 15 s 
through a mouthpiece connected to a mercury manometer. The height of the 
mercury column was maintained at 40 mm. There was a small air leak in the 
system to prevent closing of the glottis. The test was repeated until a 
reproducible response was obtained and the pressure curves on visual 
inspection allowed measurements of the pressure changes. The Valsalva ratio 
(VR) was calculated as the ratio of the shortest RR interval during or after phase 
II of the maneuver to the longest RR interval in phase IV of the maneuver. 
Measurement of the blood pressure response to Valsalva maneuver relied on 
single beats before and during the test, and the following parameters were 
calculated: maximal drop of the mean blood pressure during phase II compared 
to the level before the start of the test, the peak of the mean blood pressure at 
the end of late phase II (recovery), overshoot in the phase IV, maximal pulse 
pressure drop during phase II and pressure recovery time. Direct readings of the 
calculated mean made by the TFM were used for mean blood pressure levels. 
The heart rate variability with deep breathing was performed in the supine 
position over 9 respiratory cycles; the best six responses were chosen and the 
respective respiratory sinus arrhythmia (RSA) amplitudes were averaged. RSA 
amplitude was defined as the difference between the end of expiration and end 
of inspiration in heart rate.  
After these tests, a 10-minute 70° tilted phase followed. Responses to passive tilt 
were defined either as orthostatic hypotension (OH) or postural orthostatic 
tachycardia (POTS). OH was defined as a sustained reduction of systolic blood 
pressure of at least 20 mm Hg or diastolic blood pressure of 10 mm Hg within 3 
min of head-up tilt to 70° on a tilt table, and POTS was defined as the presence of 
symptoms of orthostatic intolerance associated with the increment of heart rate 
(HR) ≥30 bpm for adults, and ≥40 bpm for patients younger than 19 years on 
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passive tilt and in the absence of orthostatic hypotension. (Freeman et al., 2011) 
All results were interpreted according to the cardiovagal index (parasympathetic 
function) and adrenergic index (sympathetic function) of the CASS. (Low, 1993) 
 
 
2.3. Quantitative Sudomotor Axon Reflex Test (QSART)  
 
Patients were rested in supine position 15 minutes before the test. Recordings 
were performed in an acclimatized room kept on a stable controlled 
temperature. 
QSART was performed with the Q-Sweat (WR Medical Electronics Co 
Maplewood, MN, USA). Recording sites were: 1) the medial forearm (75 % 
distance from the ulnar epicondile to the pisiform bone); 2) the proximal leg (5 
cm distal to the fibular head laterally); 3) the distal leg (5 cm proximal to the 
medial malleolus medially); 4) proximal foot over the extensor digitorum brevis 
muscle. Multicompartment chambers (sampling area 0.7871 cm2, volume 0.1229 
cm3) were used for evoked responses. Chambers were first assembled according 
to the manufacturer recommendation. Recording sites were cleaned with the 
alcohol and chambers were placed water-tight. Chambers were then filled with 
10% acetylcholine (Acetylcholine iodide A7000, Sigma, UK) w/v in sterile water. 
Sweat production below the sweat compartment of the chamber was 
continuously measured by circulating air connected to a high precision 
hygrometer. Gel Trode return electrodes were placed about 5 cm next to the 
chamber. The stimulation was not started until the baseline sweat was flat, 
around 50 nanoliters/minute and all channels gave similar baseline sweat 
output (difference < 15 %). After the baseline values were obtained, 
iontophoresis of acetylcholine into the skin was performed by passing a 2 mA of 
constant current across the skin for 5 min. Previously published age and gender 
dependent reference values for sweat volume of each recording site were used. 
(Novak, 2011) Data were presented relative to the lower limit for the age group 
for hypohidrosis or upper limit for the age group for hyperhidrosis. Sudomotor 




2.4. Plasma catecholamine levels 
 
Blood samples were collected directly from a peripheral vein catheter in chilled 
tubes containing EGTA and reduced glutathione for determination of plasma 
catecholamine levels in the 10th minute of the supine phase and in the 10th 
minute of the tilted phase (Kabevette® N, Kabe Labortechnik GmbH). Plasma 
levels of catecholamine were measured on high pressure liquid chromatography 
(HPLC Prominence; Shimadzu GmbH) with an electrochemical detector CLC 100 
(Chromsystems GmbH, Germany) using a commercially available HPLC kit and a 
reverse phase analytical column for HPLC analysis of catecholamines in plasma 







Primary outcome was to the determine prevalence of cardiovascular autonomic 
system pathology using autonomic tests in CIS patients compared to healthy 
controls. This was assessed by: 1) the proportion of patients with pathological 
adrenergic index of the CASS score in CIS patients compared to healthy controls; 
2) the proportion of patients with pathological cardiovagal index of the CASS 
score in CIS patients compared to healthy controls. 
Secondary outcomes were: 1) to determine the prevalence of sudomotor 
abnormalities in CIS patients assessed by sudomotor index of the CASS; 2) to 
determine the prevalence and the degree of autonomic dysfunction according to 
CASS; 3) to determine is there a difference in catecholamine levels in patients 
with and without autonomic dysfunction. 
 
 
2.6. Statistical analysis 
Statistical analysis was performed using the IBM SPSS software, version 20. The 
Kolmogorov-Smirnov test was applied to test whether the data have a normal 
distribution. Differences in the distribution of qualitative variables were 
determined with the χ2 test, while the differences in quantitative variables were 
determined with the use of parametric t-test. P values less than 0.05 were 







During the study period 24 patients and 17 healthy controls were enrolled. 
There was no statistical difference in age (25,9 vs 24,06; p=0,213) and gender 
(17 females in group 1 and 7 in group 2; p=0,058). In the CIS group there were 7 
cases of optic neuritis, 6 of incomplete transverse myelitis, 8 
brainstem/cerebellar, 2 cases of hemispheral and 1 multifocal type of CIS. 
Median EDSS was 1.0 (range, 0-2.0). Seven out of 24 patients (29,2%) 
complained of symptoms of orthostatic intolerance, but only 4 of them had 
positive adrenergic index (Pearson Chi-Square = 0.202, p=0.653).  
 
3.2. Primary outcomes  
 
The median time from the index relapse to the autonomic investigation was 54.5 
days (6-273 days). There was no difference in proportion of patients with 
pathological blood pressure response to Valsalva maneuver or to passive tilt 
between groups. The proportion of CIS patients with pathological adrenergic 
index was statistically significantly higher compared to healthy controls. On the 
other hand, there was no difference in cardiovagal index between groups. There 
was no difference in the proportion of pathological Valsalva ratio or respiratory 
sinus arrhythmia between groups. Values for all these data are presented in 
Table 1. On the other hand, the mean Valsalva ratio was significantly higher in 
the CIS group compared to healthy controls (Table 2). 
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Adrenergic index positively correlated with the EDSS (Pearson’s Chi square, 
p=0.041), meaning that patients with normal adrenergic index had lower EDSS.  
In the CIS group there were 5 cases of POTS, while we did not identify any cases 
of POTS in the healthy control group, although this did not reach statistical 
significance. On the other hand, CIS patients had significantly higher chance for 
pathological HUTT response compared to healthy controls (Table 1). 
 
3.3. Secondary outcomes 
 
3.3.1. QSART 
Altogether 16 patients participated in the QSART substudy. Out of them, 8 had a 
pathological response on at least one tested site (Figure 1). Hypohydrosis was 
present in 4 patients and persistent foot sweating in one patient. Sweat 
production in the forearm was reduced of 2 patients (6% and 30% (patients 2 
and 5 in the Table 3, respectively)) and in the foot of 2 patients (35% and 42% 
(patients 1 and 10 in the Table 3, respectively)). Sweat production was increased 
in the forearm of 1 patient (5%, patient 14 in the Table 3), distal leg in 2 patients 
(17% and 10% (patients 11 and 16 in the Table 3, respectively)), and in the foot 
of 1 patient (7%, patient 15 in the Table 3). Five patients had sudomotor index of 
1 (four had hypohydrosis < 50% minimal referent value and one had persistent 
foot hyperhidrosis) (Table 3).  
 
3.3.2. CASS 
When combining adrenergic, cardiovagal and sudomotor indicies into CASS, 8 
patients (50%) had evidence of autonomic dysfunction, 7 mild and one 
moderate. It should be noted that none of the patients had parasympathetic 
dysfunction (Table 3).  
 
3.3.3. Plasma catecholamine levels 
Plasma catecholamine levels were determined in 15 patients; in one the blood 
withdrawal was not successful due to obstruction of the peripheral vein catheter. 
There was no difference in epinephrine and norepinephrine levels in the supine 
and standing positions between patients with or without sympathetic nervous 





Results of this study have shown autonomic dysfunction to be present in the 
earliest stages of MS. This autonomic dysfunction can primarily manifest as an 
effect on the sympathetic nervous system while the parasympathetic nervous 
system seems to be preserved in the early stages of the disease. This finding is in 
line with previous studies, which showed sympathetic nervous system 
dysfunction during relapses compared to patients with stable disease. 
(Flachenecker et al., 2011; Adamec et al., 2013) The finding that the mean 
Valsalva ratio was significantly higher in the CIS group compared to healthy 
controls indicates sympathetic vasomotor dysfunction in the CIS group, which 
further supports predominantly sympathetic nervous system dysfunction in 
active phases of MS. (Sandroni et al., 1991)  
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However, when interpreting ANS dysfunction in MS, one has to bear in mind that 
the definition of cardiovascular autonomic dysfunction in MS patients is 
controversial. Some authors are arguing that cardiovascular dysautonomia in MS 
should be diagnosed using a definition of at least one abnormal cardiac 
autonomic test, while others require at least two abnormal studies. Recently 
performed meta-analysis showed that the proportion of patients with autonomic 
dysfunction was two-fold higher when using the definition of only one abnormal 
autonomic test (42.1%) compared to that using at least two abnormal results 
(18.8%). (Racosta et al., 2015). However, interpretation of autonomic 
dysfunction in the form of CASS overcomes this problem. Direct disturbances of 
the sympathetic cardiac function in MS were visualized with I-123 MIBG 
myocardial scintigraphy, further supporting importance of ANS in MS 
(Lorberboym et al., 2008). Unlike sympathetic dysfunction, two studies have 
shown parasympathetic dysfunction progress during the course of the disease 
and that it is related to progression of disability measured with EDSS. 
(Flachenecker et al., 2001; Nasseri et al., 1999) It seems that parasympathetic 
dysfunction is driven by the disease pathology itself, although in the present 
study sympathetic cardiac dysfunction correlated with the EDSS, as well. 
Another finding of our study is that most of the patients with sympathetic 
dysfunction do not have symptoms of orthostatic intolerance. This is in line with 
the studies showing that patients with structural disorders of the autonomic 
nervous system, in spite of their extensive pathologic changes, tend to harbor 
proportionally fewer symptoms; for example, the majority of patients do not 
realize when their systolic blood pressure drops by nearly 90 mmHg (Arbogast 
et al., 2009). Another finding supporting this discrepancy is the poor correlation 
between the autonomic questionnaires with the outcome of autonomic tests 
(Labuz-Roszak and Pierzchala, 2007). 
Cardiac autonomic dysfunction in MS has several implications. The first one is 
the possibility of increased risk of cardiac arrhythmias in MS patients with 
severe cardiac autonomic dysfunction. It has been shown that MS is associated 
with prolonged P wave duration and increased P wave duration and dispersion, 
compared to healthy controls (Kocer et al., 2005). More importantly, prolonged 
P-wave duration and increased P wave duration and dispersion have been 
reported to carry an increased risk for atrial fibrillation (Dilaveris et al., 1998). 
This can have important clinical implication, especially regarding treatment of 
MS patients. Various cardiac arrhythmias have been reported during 
corticosteroid therapy for MS relapses, and sinus bradycardia and atrial 
fibrillation were detected more commonly in patients with history of urinary 
dysfunction, thus patients with ANS dysfunction (Vasheghani-Farahani et al., 
2011). In addition, the chronic use of many drugs commonly used by MS patients 
could further downregulate sympathetic nervous system by interfering with 
norepinephrine synthesis/release and/or interfering with the function of the 
adrenergic receptors in both the brain and in the periphery (Sternberg, 2012). It 
has even been suggested that sympathetic nervous system dysfunction in 
combination with norepinephrine levels would have the potential to identify MS 
patients who have a reduced response to immunomodulatory therapies. 
(Sternberg, 2012). On the other hand, new oral MS therapy, like fingolimod, is 
known to have cardiac side-effects, and one case report suggested that some 
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types of arrhythmias associated with fingolimod might be related to ANS 
dysfunction (Gialafos et al., 2014). 
The second implication is the influence of autonomic dysfunction on fatigue, 
which is one of the most common symptoms of MS. Several studies have shown 
that in patients suffering from fatigue, fatigue experience is associated with 
decreased blood pressure or with sympathetic and parasympathetic autonomic 
dysfunction. (Freeman and Komaroff, 1997; Flachenecker et al., 2003)  
It has earlier been mentioned that norepinephrine levels together with 
sympathetic nervous system dysfunction may have the potential to identify MS 
patients who have a reduced response to therapy. While one study showed that 
resting plasma norepinephrine was significantly lower in MS patients compared 
to healthy controls (Keller et al., 2014), and another study showed that 
norepinephrine and epinephrine levels are significantly lower in active MS 
patients compared to stable MS patients (Flachenecker et al., 2001), in the 
present study we were not able to show differences in catecholamine levels in 
MS patients with positive CASS compared to MS patients with negative CASS. 
Furthermore, we have shown that half of the CIS patients have varied 
pathologies on QSART. Thermoregulation has, to the best of our knowledge, only 
been studied once in CIS patients (only in patients with optic neuritis) with 
sympathetic skin response. This study has shown increased latencies, indicating 
sudomotor failure (Saari et al., 2010). QSART has rarely been studied in MS, 
mainly because it is considered that an absent response indicates a lesion of the 
postganglionic axon. However, with increased duration of the preganglionic 
lesion the response may become abnormal. This has been shown nicely in a 
study investigating cholinergic sweating responses with pilocarpine 
iontophoresis. Authors observed diminished peripheral sweating responses as a 
consequence of impairments in autonomic control of sudomotor function. (Davis 
et al., 2005) The importance of identifying thermoregulatory disturbance in MS 
is seen from several observations: 1) pathophysiological principle of 
temperature-induced conduction block in demyelinated axonal segments 
(Uhthoff's phenomenon), 2) fluctuations in body temperature can be 
problematic for MS patients when infections have been masked due to the 
absence of a typical fever response, resulting in serious medical conditions, 3) 
heat induced fatigue and 4) effects of heat sensitivity to exercise (Davis et al., 
2010).  
While CASS has been investigated in several central and peripheral nervous 
system disorders, this is the first study investigating CASS score in early MS 
(Lipp et al., 2009). CASS detected sympathetic nervous system dysfunction in 
half of the CIS patients, proving to be a good option for detection of autonomic 
dysfunction in MS, as well. 
The limitations of this study are the relatively small number of patients enrolled 
and that we only enrolled healthy controls for the testing of the cardiovascular 
autonomic system. However, the number of patients is comparable to all other 
previous studies investigating autonomic dysfunction in MS, and for QSART and 
catecholamines well established normal values exist.  
In conclusion, CASS is able to detect autonomic nervous system dysfunction in 
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Table 1. Differences in the proportion of positive main sympathetic and 
parasympathetic indexes between CIS patients and healthy controls.  
 CIS (n=24) Healthy controlos 
(n=17) 
p value 
Valsalva ratio 1 1 1.000 
RSA 0 0  
Valsalva BP 9 2 0.150 
OH 2 0 0.502 
POTS 5 0 0.065 
HUTT (OH or POTS) 7 0 0.029* 
Adrenergic index 
(CASS)  
12 2 0.018* 
Cardiovagal index 
(CASS) 
1 0 1.000 
RSA respiratory sinus arrhythmia; Valsalva BP blood pressure response to 
Valsalva maneuver, OH orthostatic hypotension; POTS postural orthostatic 








Group Mean SD p value 
RSA CIS 28.25 8.13 0.671 
HC 25.36 5.26 
VR CIS 2.27 0.32 0.045* 
HC 2.07 0.29 


















Table 3. Characteristics of the subset of patients included in the Quantitative 
Sudomotor Axon Reflex Test and catecholamine measurement part of the study. 







1 TM 0 0 1 1 
2 TM 0 0 1 1 
3 B 1 0 0 1 
4 TM 0 0 0 0 
5 ON 0 0 1 1 
6 ON 0 0 0 0 
7 ON 0 0 0 0 
8 ON 1 0 0 1 
9 TM 0 0 0 0 
10 B 3 0 1 4 
11 H 0 0 0 0 
12 B 0 0 0 0 
13 ON 0 0 0 0 
14 TM 0 0 0 0 
15 TM 0 0 1 1 
16 B 1 0 0 1 
ON optic neuritis; TM transverse myelitis; B brainstem, H hemispheric type of 
CIS. 
 
Table 4. Differences in catecholamine measurements between the patients with 





St. deviation p value 
ESu 0 0.19 0.18 0.646 
1 0.23 0.21 
ESt 0 0.29 0.21 0.935 
1 0.28 0.17 
NSu 0 1.51 0.41 0.873 
1 1.43 1.26 
NSt 0 3.06 1.14 0.619 
1 3.45 1.66 
ESu – supine epinephrine; ESt – standing epinephrine; NSu – supine 
















Figure 1. Shows proportion of patients with different responses on Quantitative 
Sudomotor Axon Reflex Test and Composite Autonomic Scoring Scale in 16 
patients participating in the substudy. 
 
 
